Drugs

, Volume 64, Issue 14, pp 1575–1596

Fondaparinux Sodium

A Review of its Use in the Prevention of Venous Thromboembolism Following Major Orthopaedic Surgery
  • Neil A. Reynolds
  • Caroline M. Perry
  • Lesley J. Scott
Adis Drug Evaluation
  • 110 Downloads

Summary

Abstract

Fondaparinux sodium (Arixtra®; fondaparinux) is the first of a new class of synthetic pentasaccharide anticoagulants that bind to antithrombin and inhibit the action of factor Xa.

In three large, well designed trials, subcutaneous fondaparinux 2.5mg once daily was more effective than subcutaneous enoxaparin sodium (enoxaparin) 30mg twice daily or 40mg once daily at preventing venous thromboembolism (VTE) at day 11 in patients undergoing hip replacement, elective major knee or hip fracture surgery; a fourth trial demonstrated similar efficacy to enoxaparin 30mg twice daily in hip replacement. Fondaparinux recipients had a lower incidence of proximal deep vein thrombosis (DVT) in two studies. In a meta-analysis of the four trials, patients receiving fondaparinux had a >50% reduction in the relative risk of VTE at day 11. Fondaparinux compared favourably with enoxaparin in several pharmacoeconomic analyses.

In a large, controlled trial in hip fracture patients, extended prophylaxis with fondaparinux (duration 25–31 days) substantially reduced the incidence of VTE at day 25–32 compared with prophylaxis for 6–8 days, and was a cost-effective treatment strategy. Moreover, extended prophylaxis significantly decreased the rate of proximal, total and distal DVT and symptomatic VTE.

Fondaparinux was generally well tolerated in clinical trials in patients undergoing major orthopaedic surgery. However, following major knee surgery and in a meta-analysis of pooled data from four trials, fondaparinux recipients had a significantly higher incidence of overt bleeding with a bleeding index ≥2, but no increase in fatal bleeding, bleeding into a critical organ or bleeding leading to reoperation. The bleeding risk is related to the timing of the first dose and when fondaparinux was initiated between 6 and 8 hours after surgery, the bleeding risk was similar to enoxaparin. Extended prophylaxis with fondaparinux was not associated with a significantly increased risk of bleeding events.

In conclusion, fondaparinux is more effective than enoxaparin at preventing postoperative VTE in patients undergoing elective hip replacement, major knee or hip fracture surgery. Extended therapy with fondaparinux considerably increases its efficacy without a significant increase in the incidence of bleeding episodes. Fondaparinux was generally well tolerated in clinical trials. Fondaparinux is an effective and useful alternative to low molecular weight heparins for the prevention of VTE following major orthopaedic surgery.

Pharmacological Properties

Fondaparinux sodium (fondaparinux), a synthetic pentasaccharide anticoagulant, selectively binds to antithrombin (AT), catalysing the inhibition of factor Xa. The in vitro antifactor Xa activity of fondaparinux is ≈700 anti-XaIU/mg.

In vitro, fondaparinux does not bind to platelets or platelet factor 4 or inhibit platelet aggregation. It had no clinically significant effects on the activated partial thromboplastin time, prothrombin time, AT levels or the bleeding time in healthy volunteers.

After subcutaneous injection, fondaparinux is rapidly and completely absorbed, and shows linear pharmacokinetics over a 2–8mg dose range in healthy volunteers. The volume of distribution (8.2–10.2L) suggests that drug distribution is limited to the vascular compartment only. In plasma, fondaparinux binds almost exclusively to AT.

Fondaparinux is primarily excreted unchanged in the urine, with a correlation between clearance of fondaparinux and creatinine. In vitro studies suggest that fondaparinux does not undergo metabolism by liver enzymes and does not interfere with cytochrome P450-mediated metabolism of other drugs.

Therapeutic Efficacy

At 11 days’ follow-up, subcutaneous fondaparinux 2.5mg administered once daily for 5–9 days prevented venous thromboembolism (VTE) following major orthopaedic surgery in four large, well designed studies. Fondaparinux was more effective than standard prophylactic dosages of subcutaneous enoxaparin sodium (enoxaparin) at preventing postoperative VTE in patients undergoing elective hip replacement, major knee or hip fracture surgery. A meta-analysis showed that fondaparinux recipients had a >50% relative risk reduction of VTE by day 11 compared with those receiving enoxaparin undergoing major orthopaedic surgery. Furthermore, secondary endpoint analysis showed that by day 11, patients receiving fondaparinux had a significantly lower rate of total or distal deep vein thrombosis (DVT) in all studies and proximal DVT in two trials than enoxaparin recipients.

Prophylaxis with fondaparinux for 25–31 days after hip fracture surgery substantially reduced the incidence of VTE by day 25–32 compared with fondaparinux treatment for 6–8 days. Moreover, prolonged prophylaxis was associated with a lower incidence of proximal, total or distal DVT and fewer symptomatic VTEs than treatment for the standard duration.

Tolerability

Fondaparinux is generally well tolerated when used for the prophylaxis of VTE in patients undergoing major orthopaedic surgery. A meta-analysis of pooled data from the four trials in major orthopaedic surgery showed a significantly higher incidence of overt bleeding with a bleeding index ≥2 with fondaparinux compared with enoxaparin, but no increase in fatal bleeding, bleeding into a critical organ or bleeding leading to reoperation.

A low incidence of thrombocytopenia was seen in patients receiving fondaparinux (2–4.9%) or enoxaparin (3–5.3%). Thrombocytopenia was not reported as a serious adverse event in any trial, and no cases of heparin-induced thrombocytopenia were reported.

Pharmacoeconomic Studies

No significant increase in the incidence of bleeding episodes was observed in patients receiving extended or standard-duration prophylaxis. Fondaparinux compared favourably with enoxaparin in pharmacoeconomic studies in patients undergoing major orthopaedic surgery or elective major knee or hip fracture surgery. In patients undergoing hip replacement, fondaparinux was cost effective with respect to the incremental cost-effectiveness ratio per VTE avoided compared with enoxaparin 40mg once daily, but not 30mg twice daily. Fondaparinux was generally cost saving relative to enoxaparin at timepoints ≥90 days after surgery. Extended prophylaxis with fondaparinux (duration of treatment 28 days) in patients undergoing surgery for hip fracture was also cost effective, and was cost saving relative to enoxaparin at timepoints ≥90 days after surgery.

References

  1. 1.
    Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119 (1 Suppl.): 132S–75SPubMedCrossRefGoogle Scholar
  2. 2.
    Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003 Apr 14; 163(7): 759–68PubMedCrossRefGoogle Scholar
  3. 3.
    Bick RL. Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism. Drugs 2000 Sep; 60(3): 575–95PubMedCrossRefGoogle Scholar
  4. 4.
    Petitou M, Duchaussoy P, Herbert J-M, et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrom-botic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 2002; 28(4): 393–402PubMedCrossRefGoogle Scholar
  5. 5.
    Agnelli G, Bergqvist D, Cohen A, et al. A randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra®) and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS study [abstract no. 40]. Blood 2003 Nov; 102 (11 Pt 1): 15aGoogle Scholar
  6. 6.
    Cohen AT, Davidson BL, Gallus AS, et al. Fondaparinux for the prevention of VTE in acutely ill medical patients [abstract no. 42]. Blood 2003 Nov; 102 (11 Pt 1): 15aCrossRefGoogle Scholar
  7. 7.
    The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003 Oct; 349(18): 1695–702CrossRefGoogle Scholar
  8. 8.
    Büller HR, Davidson BL, Decousus H, et al., for The Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med 2004 Jun 1; 140(11): 867–73PubMedGoogle Scholar
  9. 9.
    Coussement PK, Bassand J-P, Convens C, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study. Eur Heart J 2001 Sep; 22(18): 1716–24PubMedCrossRefGoogle Scholar
  10. 10.
    Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent: a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999; 81(2): 214–20PubMedGoogle Scholar
  11. 11.
    Keam SJ, Goa KL. Fondaparinux sodium. Drugs 2002; 62(11): 1673–85; discussion 1686-7PubMedCrossRefGoogle Scholar
  12. 12.
    Herbert JM, Petitou M, Lormeau JC, et al. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15(1): 1–26CrossRefGoogle Scholar
  13. 13.
    Walenga JM, Jeske WP, Bara L, et al. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86(1): 1–36PubMedCrossRefGoogle Scholar
  14. 14.
    Samama MM, Bara L, Walenga J. Comparative mechanism of action and pharmacokinetics of pentasaccharide and LMW heparins. 16th International Congress on Thrombosis; dy2000 May 5–8; Porto, 99–102Google Scholar
  15. 15.
    Sanofi-Synthelabo. Arixtra summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/ [Accessed 2003 Sep 23]
  16. 16.
    Messmore Jr HL, Griffin B, Fareed J, et al. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. Ann N Y Acad Sci 1989; 556: 217–31PubMedCrossRefGoogle Scholar
  17. 17.
    Boneu B, Necciari J, Cariou R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74(6): 1468–73PubMedGoogle Scholar
  18. 18.
    Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998 Jun; 91(11): 4197–205PubMedGoogle Scholar
  19. 19.
    Petitou M, Duchaussoy P, Jaurand G, et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540). J Med Chem 1997 May 23; 40(11): 1600–7PubMedCrossRefGoogle Scholar
  20. 20.
    Lormeau JC, Herault JP, Gaich C, et al. Determination of the anti-factor Xa activity of the synthetic pentasaccharide SR 90107 A/ORG 31540 and of two structural analogues. Thromb Res 1997 Jan 1; 85(1): 67–75PubMedCrossRefGoogle Scholar
  21. 21.
    Bendetowicz AV, Bara L, Samama MM. The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma. Thromb Res 1990; 58: 445–54PubMedCrossRefGoogle Scholar
  22. 22.
    Brufatto N, Ward A, Nesheim ME. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 2003; 1: 1258–63PubMedCrossRefGoogle Scholar
  23. 23.
    Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 32701: comparison with the ‘synthetic pentasaccharide’ (SR 90107/ORG 31540) and standard heparin. Circ Res 1996; 79(3): 590–600PubMedCrossRefGoogle Scholar
  24. 24.
    Walenga JM, Petitou M, Lormeau JC, et al. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987; 46: 187–98PubMedCrossRefGoogle Scholar
  25. 25.
    Carrie D, Caranobe C, Saivin S, et al. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. Blood 1994; 84(8): 2571–7PubMedGoogle Scholar
  26. 26.
    Lormeau JC, Herault JP, Herbert JM. Antithrombin-mediated inhibition of factor Vila-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb Haemost 1996 Jul; 76(1): 5–8PubMedGoogle Scholar
  27. 27.
    Gerotziafas GT, Bara L, Bloch MF, et al. Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma. Blood Coagul Fibrinolysis 1998; 9(7): 571–80PubMedCrossRefGoogle Scholar
  28. 28.
    Pieters J, Lindhout T, Willems G. Heparin-stimulated inhibition of factor IXa generation and factor IXa neutralization in plasma. Blood 1990 Aug 1; 76(3): 549–54PubMedGoogle Scholar
  29. 29.
    Wiebe EM, Stafford AR, Fredenburgh JC, et al. Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide. J Biol Chem 2003 Sep 12; 278(37): 35767–74PubMedCrossRefGoogle Scholar
  30. 30.
    Pieters J, Willems G, Hemker HC, et al. Inhibition of factor IXa and factor Xa by antithrombin III/heparin during factor X activation. J Biol Chem 1988 Oct 25; 263(30): 15313–8PubMedGoogle Scholar
  31. 31.
    Hérault JP, Gaich C, Bono F, et al. The structure of synthetic oligosaccharides in relation to factor IXa inhibition. Thromb Haemost 2002; 88(3): 432–5PubMedGoogle Scholar
  32. 32.
    Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost 1995; 74(6): 1474–7PubMedGoogle Scholar
  33. 33.
    Horne 3rd MK, Chao ES. The effect of molecular weight on heparin binding to platelets. Br J Haematol 1990; 74(3): 306–12PubMedCrossRefGoogle Scholar
  34. 34.
    Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8(2): 114–7PubMedCrossRefGoogle Scholar
  35. 35.
    Savi P, Chong B, Greinacher A, etal. Effect of fondaparinux on platelet activation in the presence of heparin-dependent anti-platelet antibodies. A blinded comparative multicenter study with unfractionated heparin [abstract no. 1145]. Blood 2003 Nov; 102 (11 Pt 1): 319aGoogle Scholar
  36. 36.
    Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin App Thromb Hemost 1999; 5(4): 259–66CrossRefGoogle Scholar
  37. 37.
    Walenga JM, Fareed J. Relative contribution of factor Xa and factor IIa. Inhibition in the mediation of the antithrombotic actions of LMWHs and synthetic heparin pentasaccharides. Thromb Haemorrh Disord 1991; 3(2): 53–9Google Scholar
  38. 38.
    Pottier P, Planchon B, Truchaud F, et al. Efficacy of pentasaccharide on a prethrombosis model based on a calibrated stasis by the increase in up-stream venous pressure. Blood Coagul Fibrinolysis 2003; 14(6): 587–91PubMedCrossRefGoogle Scholar
  39. 39.
    Iqbal O, Silver P, Walenga JM, et al. Neutralization of the anticoagulant effect of a synthetic heparinomimetic (pentasaccharide) by heparinase I: potential clinical implications [abstract no. P2246]. 18th Congress of the International Society on Thrombosis and Haemostasis; 2001 Jul 6–12; ParisGoogle Scholar
  40. 40.
    Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor Vila to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106(20): 2550–4PubMedCrossRefGoogle Scholar
  41. 41.
    Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 1–9PubMedCrossRefGoogle Scholar
  42. 42.
    Ollier C, Faaij RA, Santoni A, et al. Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 31–7PubMedCrossRefGoogle Scholar
  43. 43.
    Faaij RA, Burggraaf J, Schoemaker RC, et al. Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. Br J Clin Pharmacol 2002; 54(3): 304–8PubMedCrossRefGoogle Scholar
  44. 44.
    Mant T, Fournié P, Ollier C, et al. Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 39–45PubMedCrossRefGoogle Scholar
  45. 45.
    Paolucci F, Claviés MC, Donat F, et al. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 2002; 41 Suppl. 2: 11–8PubMedCrossRefGoogle Scholar
  46. 46.
    Lagrange F, Vergnes C, Brun JL, et al. Absence of placental transfer of pentasaccharide (fondaparinux, Arixtra®) in the dually perfused human cotyledon in vitro. Thromb Haemost 2002; 87(5): 831–5PubMedGoogle Scholar
  47. 47.
    Lieu C, Shi J, Donat F, et al. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin Pharmacokinet 2002; 41 Suppl. 2: 19–26PubMedCrossRefGoogle Scholar
  48. 48.
    Lassen MR, Bauer KA, Eriksson BI, et al., for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus pre-operative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002 May 18; 359: 1715–20PubMedCrossRefGoogle Scholar
  49. 49.
    Turpie AGG, Bauer KA, Eriksson BI, et al., for thePENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002 May 18; 359: 1721–6PubMedCrossRefGoogle Scholar
  50. 50.
    Bauer KA, Eriksson BI, Lassen MR, et al., for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001 Nov; 345(18): 1305–10PubMedCrossRefGoogle Scholar
  51. 51.
    Eriksson BI, Bauer KA, Lassen MR, et al., for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001 Nov; 345(18): 1298–304PubMedCrossRefGoogle Scholar
  52. 52.
    Eriksson BI, Lassen MR, for the PENTasaccharide in HIp-FRActure Surgery Plus (PENTHIFRA Plus) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003 Jun 9; 163: 1337–42PubMedCrossRefGoogle Scholar
  53. 53.
    Turpie AGG, Gallus AS, Hoek JA, et al., for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001 Mar 1; 344(9): 619–25PubMedCrossRefGoogle Scholar
  54. 54.
    Turpie AGG, Bauer KA, Eriksson BI, et al., for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002 Sep 9; 162(16): 1833–40PubMedCrossRefGoogle Scholar
  55. 55.
    Turpie AGG, Eriksson BI, Lassen MR, et al. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc 2002 Winter; 11(4): 182–8PubMedGoogle Scholar
  56. 56.
    Organon Sanofi-Synthelabo LLC. Arixtra® (fondaparinux sodium) injection prescribing information [online]. Available from URL: http://www.fda.gov/cder/approval/index.htm [Accessed 2003 May 11]
  57. 57.
    Turpie A, Bauer K, Eriksson B, et al., on behalf of the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration [letter]. Thromb Haemost 2003 Aug; 90(2): 364–6PubMedGoogle Scholar
  58. 58.
    Lassen M, Bauer KA, Eriksson BI, et al. Absence of transaminase increase after 4-week administration of fondaparinux (Arixtra®), a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study [abstract no. P2052]. J Thromb Haemost 2003; 1 Suppl. 1: P2052Google Scholar
  59. 59.
    Gordois A, Posnett J, Borris L, et al. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost 2003 Oct; 1(10): 2167–74PubMedCrossRefGoogle Scholar
  60. 60.
    Sullivan SD, Davidson BL, Kahn SR, etal. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmaco-economics 2004; 22(9): 605–20CrossRefGoogle Scholar
  61. 61.
    Wade WE, Spruill WJ, Leslie RB. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty. Am J Orthop 2003 Apr; 32(4): 201–5PubMedGoogle Scholar
  62. 62.
    Spruill WJ, Wade WE, Leslie RB. A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty. Am J Ther 2004; 11(1): 3–8PubMedCrossRefGoogle Scholar
  63. 63.
    Annemans L, De Groot K. Cost-effectiveness of fondaparinux (Arixtra®) compared with enoxaparin as prophylaxis against venous thromboembolism following major orthopedic surgery [abstract no. P2053]. 19th Congress of the International Society on Thrombosis and Haemostasis; 2003 Jul 12–18; BirminghamGoogle Scholar
  64. 64.
    Slof J, Magaz S, Badia X. Clinical and economic outcomes of fondaparinux vs. enoxaparin in the prophylaxis of venous thromboembolism after major orthopedic surgery in Spain [poster]. 6th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2003 Nov 9–11; BarcelonaGoogle Scholar
  65. 65.
    Stumpo C, Kahn S, Martineau J, et al. Pharmacoeconomic analysis of fondaparinux for the prevention of thromboembolic events in orthopedic surgical patients [abstract]. Can J Hosp Pharm 2003 Aug; 56 Suppl. 3: 29Google Scholar
  66. 66.
    Sullivan SD, Kahn SR, Muntz JE. Fondaparinux is cost-effective compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing surgery for hip replacement [abstract no. 190]. Pharmacotherapy 2003 Oct; 23(10): 1355Google Scholar
  67. 67.
    Sullivan SD, Kahn SR, Muntz JE. Fondaparinux is cost-effective compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing surgery for knee replacement [abstract no. 191]. Pharmacotherapy 2003 Oct; 23(10): 1355Google Scholar
  68. 68.
    Sullivan SD, Kahn SR, Muntz JE. Fondaparinux is cost-effective compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing surgery for hip fracture [abstract no. 189]. Pharmacotherapy 2003 Oct; 23(10): 1355Google Scholar
  69. 69.
    Sullivan SD, Kwong L. A cost effectiveness analysis of extending prophylaxis from one week to four weeks with fondaparinux after hip fracture surgery [abstract no. 1827]. Blood 2003 Nov 16; 102 (11 Pt 1): 502aGoogle Scholar
  70. 70.
    Sullivan SD, Kwong L. Extended prophylaxis treatment with fondaparinux is cost effective compared with enoxaparin after hip fracture surgery [abstract no. 5771]. Blood 2003 Nov 16; 102(11 Pt 2): 510bGoogle Scholar
  71. 71.
    Sullivan SD, Kwong L. The incremental cost per life year saved of extended prophylaxis with fondaparinux versus enoxaparin after hip fracture surgery [abstract no. 1826]. Blood 2003 Nov 16; 102(11 Pt 1): 502aGoogle Scholar
  72. 72.
    Van Hout BA, Minjoulat-Rey MC, Quinlan DJ, et al. Cost-effectiveness of extending prophylaxis with fondaparinux in preventing venous thromboembolism following hip fracture surgery [poster]. 6th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2003 Nov 9–11; BarcelonaGoogle Scholar
  73. 73.
    Sanofi-Synthelabo. Arixtra® in the European Union: New treatment duration for the prophylaxis of venous thromboembolic events in patients undergoing major orthopaedic surgery [online]. Available from URL: http://en.sanofi-synthelabo.com [Accessed 2003 Dec 3]
  74. 74.
    Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001 Mar; 20(1): 1–37Google Scholar
  75. 75.
    de Moerloose P, Boehlen F. Two new antithrombotic agents (fondaparinux and ximelagatran) and their implications in anesthesia. Can J Anesth 2002; 49(6): S5–S10PubMedGoogle Scholar
  76. 76.
    Mant M, Geerts B. The Thrombosis Interest Group of Canada. Practical treatment guidelines. DVT prophylaxis in orthopedics [online]. Available from URL: http://www.tigc.org/eguidelines/dvtortho03.htm [Accessed 2003 Dec 17]
  77. 77.
    Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001 Jul; 358: 9–15PubMedCrossRefGoogle Scholar
  78. 78.
    D’Amico EA, Villaça PR, Gualandro SFM, et al. Successful use of Arixtra® in a patient with paroxysmal nocturnal hemo-globinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia [letter]. J Thromb Haemost 2003 Nov; 1(11): 2452-3PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Neil A. Reynolds
    • 1
  • Caroline M. Perry
    • 1
  • Lesley J. Scott
    • 1
  1. 1.Adis International LimitedMairangi Bay, AucklandNew Zealand

Personalised recommendations